Dipeptidyl peptidase-4 inhibitors

Dipeptidyl Peptidase 4 Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Health, Diabetes, Proteases, Dipeptidyl peptidase-4 inhibitors, Dipeptidyl peptidase, Nitriles, Chemistry, Organic compounds, Chemical compounds, Tertiary alcohols, Piperidines, Dipeptidyl-peptidase IV family, Vildagliptin

The "Dipeptidyl Peptidase 4 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dipeptidyl Peptidase 4 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Dipeptidyl peptidase 4 inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Dipeptidyl peptidase 4 inhibitors pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Dipeptidyl peptidase 4 inhibitors R&D.
  • Dipeptidyl peptidase 4 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers

Retrieved on: 
Wednesday, June 16, 2021
Clinical trials, Dipeptidyl peptidase-4 inhibitors, Bristol-Myers Squibb

ET

Key Points: 
  • ET
    GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced results from a prespecified 6-week interim analysis of its ongoing 12-week, Phase 1, placebo-controlled, single and multiple ascending dose trial of ALT-801, an investigational GLP-1/glucagon dual receptor agonist, in healthy overweight and obese volunteers.
  • All but one subject who received the 1.8 mg sc dose achieved at least 3% weight loss by Week 6.
  • Gastrointestinal adverse events have required other GLP-1 based agents to dose titrate over 16 to 20 weeks to maintain adequate tolerability.
  • The ALT-801 Phase 1 clinical trial is a placebo-controlled, first-in-human, single ascending dose (SAD) and multiple ascending dose (MAD) study in overweight and obese volunteers being conducted in Australia under a clinical trial application.

Keller Lenkner's Ashley Barriere Appointed to Plaintiffs' Steering Committee for Onglyza and Kombiglyze XR MDL

Retrieved on: 
Wednesday, December 23, 2020
Organic compounds, Drugs, Chemical compounds, Bristol-Myers Squibb, Dipeptidyl peptidase-4 inhibitors, Nitriles, Saxagliptin, Metformin, Ranitidine, Product liability

CHICAGO, Dec. 23, 2020 /PRNewswire/ -- Keller Lenkner LLC Associate Ashley Barriere has been appointed to the Plaintiffs' Steering Committee and will lead the Law & BriefingCommittee for the Onglyza and Kombiglyze XR Products Liability Litigation MDL.

Key Points: 
  • CHICAGO, Dec. 23, 2020 /PRNewswire/ -- Keller Lenkner LLC Associate Ashley Barriere has been appointed to the Plaintiffs' Steering Committee and will lead the Law & BriefingCommittee for the Onglyza and Kombiglyze XR Products Liability Litigation MDL.
  • In the lawsuits, which were consolidated into an MDL in 2018, individuals who took Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin) to treat Type 2 diabetes allege that the drugs caused serious cardiac complications.
  • "I'm honored to represent the plaintiffs in this MDL, to seek justice for those injured, and to lead the law and briefing effort," Barriere said.
  • Keller Lenkner Partner Ashley Keller chairs the Law & Briefing Committee in the Zantac (Ranitidine) Products Liability MDL, and Partner Nicole Berg sits on the Law & Briefing Subcommittee in the 3M Combat Arms Earplug Products Liability MDL.

Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)

Retrieved on: 
Monday, June 8, 2020
RTT, Bronchiectasis, Dipeptidyl peptidase, Dipeptidyl peptidase-4 inhibitors

We look forward to continuing to work with the FDA as we advance the development of brensocatib to address this urgent medical need."

Key Points: 
  • We look forward to continuing to work with the FDA as we advance the development of brensocatib to address this urgent medical need."
  • The breakthrough therapy designation for brensocatib is based on positive results from the global randomized, double-blind, placebo-controlled Phase 2 WILLOW study of brensocatib in adults with NCFBE.
  • Insmed expects to initiate a Phase 3 program for brensocatib in bronchiectasis in the second half of 2020.
  • Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase I (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis.

Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session

Retrieved on: 
Wednesday, May 20, 2020
RTT, Dipeptidyl peptidase, Peptidase, Dipeptidyl peptidase-4 inhibitors, Bronchiectasis

Insmed will hold a conference call following the oral session during which Professor Chalmers will further discuss the WILLOW data and Insmed management will provide a business assessment of brensocatib.

Key Points: 
  • Insmed will hold a conference call following the oral session during which Professor Chalmers will further discuss the WILLOW data and Insmed management will provide a business assessment of brensocatib.
  • The virtual session, titled Phase 2 Randomized Controlled Trial of DPP1 Inhibitor Brensocatib (INS1007) in Patients with Bronchiectasis: The WILLOW Study, is part of the ATS session Breaking News: Clinical Trial Results in Pulmonary Medicine.
  • Insmed will host a conference call on Wednesday, June 24, 2020 at 4:00 pm ET.
  • Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase I (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis.

Global DPP-IV Inhibitors Industry

Retrieved on: 
Tuesday, April 14, 2020
Dipeptidyl peptidase-4, Peptidase, Dipeptidyl peptidase-4 inhibitors

NEW YORK, April 14, 2020 /PRNewswire/ --DPP-IV Inhibitors market worldwide is projected to grow by US$1.7 Billion, driven by a compounded growth of 2.6%.

Key Points: 
  • NEW YORK, April 14, 2020 /PRNewswire/ --DPP-IV Inhibitors market worldwide is projected to grow by US$1.7 Billion, driven by a compounded growth of 2.6%.
  • DPP-IV Inhibitors, one of the segments analyzed and sized in this study, displays the potential to grow at over 2.6%.
  • Poised to reach over US$10.4 Billion by the year 2025, DPP-IV Inhibitors will bring in healthy gains adding significant momentum to global growth.
  • In Japan, DPP-IV Inhibitors will reach a market size of US$747.8 Million by the close of the analysis period.

Sitagliptin Market Insights Report 2019 - Global and Chinese Analysis and Forecast Market to 2024 by Manufacturers, Product Type, Application, Regions and Technology - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 12, 2019
Biotechnology, Diabetes, Health, Chemical compounds, Dipeptidyl peptidase-4 inhibitors, RTT, Merck, Sitagliptin, Triazoles, Economy of China, Chemistry, Organic compounds

The "Sitagliptin Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sitagliptin Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report has been added to ResearchAndMarkets.com's offering.
  • Sitagliptin Market Insights Report 2019 is a professional and in-depth study on the current state of the global Sitagliptin industry with a focus on the Chinese market.
  • Overall, the report provides an in-depth insight of 2014-2024 Global and Chinese Sitagliptin market covering all important parameters.
  • Through the statistical analysis, the report depicts the Global and Chinese total market of Sitagliptin industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

Global and Chinese Market Vildagliptin Market Insights, 2014-2019 & 2019-2024 by Manufacturers, Product Type, Application, and Technology - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 11, 2019
Health, Pharmaceutical, Organic compounds, Chemical compounds, Chemistry, Dipeptidyl peptidase-4 inhibitors, Nitriles, Pyrrolidines, Vildagliptin, Economy of China

The "Vildagliptin Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vildagliptin Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report has been added to ResearchAndMarkets.com's offering.
  • Vildagliptin Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Vildagliptin industry with a focus on the Chinese market.
  • Overall, the report provides an in-depth insight of 2014-2024 Global and Chinese Vildagliptin market covering all important parameters.
  • Through the statistical analysis, the report depicts the Global and Chinese total market of Vildagliptin industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

Linagliptin (CAS 668270-12-0) Market Research Report 2019

Retrieved on: 
Tuesday, August 20, 2019
Organic compounds, Dipeptidyl peptidase-4 inhibitors, Eli Lilly and Company, Chemical compounds, RTT, Linagliptin, Quinazolines, Market research

Dublin, Aug. 20, 2019 (GLOBE NEWSWIRE) -- The "Linagliptin (CAS 668270-12-0) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Dublin, Aug. 20, 2019 (GLOBE NEWSWIRE) -- The "Linagliptin (CAS 668270-12-0) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.
  • This Global Report 2019 is a result of industry experts' diligent work on Researching the world market of Linagliptin.
  • The forth chapter deals with Linagliptin market trends review, distinguish Linagliptin manufacturers and suppliers.
  • The Linagliptin global market Report 2019 key points:

Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta®

Retrieved on: 
Tuesday, June 11, 2019
Health, Biotechnology, Cardiology, Clinical trials, Pharmaceutical, Research, Science, Dipeptidyl peptidase-4 inhibitors, RTT, Chemical compounds, Organic compounds, Piperidines, Organ systems, Linagliptin, Diabetes, Gemigliptin, Metformin

These data can further support physicians in choosing the most appropriate glucose-lowering treatment for each individual patient.

Key Points: 
  • These data can further support physicians in choosing the most appropriate glucose-lowering treatment for each individual patient.
  • But, physicians considering additional therapies to lower blood glucose for their patients need a DPP-4 inhibitor with an established long-term safety profile.
  • These new data from CAROLINA, along with data from the placebo-controlled cardiovascular outcome trial CARMELINA, expand the evidence and experience with linagliptin, to provide healthcare professionals with confidence in the long-term safety profile across a broad range of patients with type 2 diabetes.
  • CAROLINA is the only DPP-4 inhibitor, active-comparator cardiovascular outcome trial.